SOC 2 Audits for Biotech Software Companies
Pharma companies, CROs, and research institutions evaluate lab and research software against GxP and 21 CFR Part 11 before trusting it with regulated data. Here is how biotech software companies scope SOC 2 as the security backbone underneath validation.
Why biotech software companies get asked for SOC 2
Biotech software — lab informatics (LIMS and ELN), bioinformatics pipelines, and clinical-trial and research platforms — sells into pharmaceutical companies, contract research organizations (CROs), and academic research institutions. Their quality and IT teams evaluate vendors against GxP expectations and 21 CFR Part 11 for electronic records and signatures, and a SOC 2 is the security backbone they expect underneath a computer system validation (CSV) effort.
Two kinds of data raise the stakes: irreplaceable research and IP such as assay data, compound libraries, and genomic datasets, and, when clinical trials are involved, subject data governed by Good Clinical Practice. Sponsors and CROs care intensely about data integrity — the ALCOA principles that records be attributable, legible, contemporaneous, original, and accurate — so reviewers probe audit trails, access controls, and change management far more deeply than a typical SaaS buyer would. SOC 2 complements GxP validation; it does not replace it.
Trust Services Criteria focus for Biotech Software
Security (the Common Criteria) is mandatory in every SOC 2 report. The other four criteria are elective — you scope them in based on what your customers actually rely on. Here is how biotech software companies typically scope them, and why:
| Criterion | Typical scope | Why it matters in Biotech Software |
|---|---|---|
| Security | Always in scope | Mandatory in every SOC 2. For biotech software, expect focus on access control to regulated records, protection of research IP, and change control over pipelines and validated environments. |
| Availability | Common | Long-running analyses and trial-critical systems make availability matter for compute-heavy pipelines and active studies; buyers want tested backups and recovery for datasets that cannot be regenerated. |
| Confidentiality | Usually in scope | Compound libraries, assay results, and genomic data are crown-jewel IP under strict confidentiality agreements. Reviewers expect strong tenant isolation, encryption, and access segregation between sponsors. |
| Processing Integrity | Common | Central to this category: when customers rely on your pipelines for accurate, reproducible results, buyers want evidence of validation, completeness, and error handling across data transformations. |
| Privacy | Sometimes | Scoped in when clinical-trial platforms hold identifiable subject data; pure research and lab-informatics tools working with de-identified or non-personal data usually leave Privacy out. |
Each elective criterion adds controls and evidence — and cost. Scope what your customers demand in security reviews, not everything at once.
Scoping decisions specific to Biotech Software
These are the Biotech Software-specific calls that shape your system description, control list, and ultimately your audit price. Settle them before you request quotes — firms price scope, not industry labels.
Draw the GxP vs non-GxP boundary
Separate systems that hold regulated records subject to 21 CFR Part 11 from research-only environments. The audited boundary and the depth of change control differ sharply, and conflating them balloons scope; be explicit about which environments carry validated status.
Part 11 audit trails and electronic signatures
For regulated records, reviewers expect tamper-evident audit trails and controlled electronic signatures. Auditors sample whether audit trails are enabled by default, protected from edits, and retained for the required record lifetime.
Data integrity across the pipeline (ALCOA)
Bioinformatics and LIMS data pass through many transformation steps. Show controls that keep records attributable and accurate end to end — versioned pipelines, checksums, and controlled reprocessing rather than silent overwrites of prior results.
Research IP confidentiality and tenant isolation
Sponsors' compound and assay data are crown-jewel IP. Demonstrate strong tenant isolation, per-tenant encryption, and access segregation so one sponsor's research can never be visible to another customer or to unauthorized internal staff.
Computer system validation handoff
Customers running CSV rely on your change and release controls as inputs to their validated state. Document how you communicate changes to validated environments so customers can maintain validation without being surprised by an update.
What a SOC 2 audit costs for biotech software companies
These are first-party published rates from accredited firms on the AuditNex network — actual prices, not survey estimates. Data as of 2026-07-26.
Quote requests priced at network rates: Withheld — 2 samples, below our 5-sample minimum.
Frameworks biotech software companies pair with SOC 2
SOC 2 is rarely the only requirement in this category. These are the frameworks most often pursued alongside it — and overlapping evidence you can reuse if you plan both from the start:
| Framework | Why it comes up alongside SOC 2 |
|---|---|
| 21 CFR Part 11 | The FDA rule for electronic records and signatures in regulated work. SOC 2 access, audit-trail, and change controls provide much of the evidence base, but Part 11 compliance is a customer-and-system-specific determination, not something SOC 2 grants. |
| GxP / computer system validation | Pharma and CRO customers must validate the systems they use. Your SOC 2 controls feed their CSV effort as supplier evidence, though the validation itself remains the customer's responsibility. |
| ISO 27001 | Global pharma sponsors frequently prefer certification. The ISMS overlaps substantially with SOC 2 Security, so both can run on one evidence base when you sell internationally. |
Finding an auditor who knows Biotech Software
Best SOC 2 auditors for healthcare › · All auditor profiles › · How we verify auditors ›
SOC 2 for Biotech Software: common questions
How does SOC 2 fit with 21 CFR Part 11 and GxP validation?
SOC 2 provides the security foundation — access control, audit trails, and change management — that Part 11 and computer system validation build on. It supports your customers' validation efforts as supplier evidence, but Part 11 compliance and CSV remain determinations they make about their own use of your system.
Why do pharma and CRO buyers care so much about data integrity?
Because regulated research and submissions depend on records being trustworthy under the ALCOA principles. Reviewers probe whether audit trails are tamper-evident, whether data can be silently overwritten, and how reprocessing is controlled — far more deeply than a typical SaaS buyer, so those controls should be solid before the audit.
Should we scope Processing Integrity for a bioinformatics platform?
Often yes. When customers rely on your pipelines to produce accurate, reproducible results, Processing Integrity tests validation, completeness, and error handling across transformations. If your platform only stores and shares data without transforming it, Security and Confidentiality may be sufficient.
How do we protect one sponsor's research from another's?
Tenant isolation is central. Demonstrate logical or physical separation, per-tenant encryption, and access segregation so no sponsor's compound or assay data is reachable by another customer or by internal staff without authorization. Auditors sampling Confidentiality will test these boundaries directly.
Get SOC 2 quotes scoped for Biotech Software
Answer five questions once — we’ll show accredited auditors that fit your scope, with transparent pricing and no sales calls. Scope it the way this guide describes: report type, criteria mix, and timeline are what drive your quotes.
Start a quote →